Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bupivacaine hydrochloride 0.75% injection
- Development stage
- Phase 4
- Lead developer
- Bofors
- Modality
- Small Molecules
- Administration
- Epidural, Ophthalmic, Parenteral, Percutaneous
01
Overview
Bupivacaine hydrochloride 0.75% injection is a sterile, long-acting amino-amide local anesthetic solution. It works by binding to the intracellular portion of voltage-gated sodium channels on neuronal membranes, preventing the influx of sodium ions and thereby inhibiting the initiation and conduction of nerve impulses. This formulation is specifically indicated for local or regional anesthesia and analgesia in surgical, diagnostic, and therapeutic procedures in adults where a high degree of muscle relaxation and prolonged effect are required. Due to the risk of cardiac arrest, the 0.75% concentration is not recommended for obstetrical anesthesia. In clinical trials, it has been evaluated for postoperative pain control in peripheral nerve blocks, such as popliteal and saphenous nerve blocks, for patients undergoing foot and ankle procedures.
- Brand names
- MarcaineSensorcaine
- Other names
- bupivacainebupivacaine HClbupivacaine HCl 0.75% injectionbupivacaine hydrochloridebupivacaine hydrochloride 0.75% injectionbupivacaine hydrochloride 0.75% solution for injection
02
Targets
SCN5A (Sodium channel protein type 5 subunit alpha)NaV alpha (Voltage-gated sodium channel alpha subunit family)
Beyond the preview
Go deeper on bupivacaine hydrochloride 0.75% injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bupivacaine hydrochloride 0.75% injection.